Samsung announced that its Galaxy Ring and Galaxy Watch devices received FDA approval in July for an upgraded sleep apnea detection feature. The AI-powered tool now tracks breathing disruptions hourly and can report mild, occasional or frequent apnea after users log at least five hours of sleep on two nights within a ten-day span. The feature is also rolling out to the Galaxy Watch 9, with Watch 7 and 8 support planned via future updates.
engadget.com
· 2026-11-03
The FDA approved ChemoCentryx's vasculitis drug Tavneos in October 2021 after a narrow advisory committee vote, despite concerns that the pivotal trial's design made its benefits hard to verify. Amgen acquired ChemoCentryx a year later, and Tavneos has since generated nearly $500 million in annual sales at roughly $220,000 per patient per year. In April 2025, the FDA proposed withdrawing the drug, citing reports of serious liver injury and evidence—surfaced through an investor lawsuit—that ChemoCentryx employees may have manipulated trial data submitted to regulators.
arstechnica.com
· 2026-10-31
HHS Secretary Robert F. Kennedy Jr. has directed the FDA to refrain from taking enforcement action against pharmacies selling six compounded peptides, including BPC-157, KPV and TB-500. The Associated Press reports the decision was made without input from FDA scientists, who generally opposed the change, and HHS says it is intended to expand patient choice while maintaining safety.
futurism.com
· 2026-10-29
Health Secretary Robert F. Kennedy Jr. has issued a Department of Health and Human Services policy stating it will not take enforcement action against compounding pharmacies that produce and sell six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The move does not formally change the drugs' regulatory status, but effectively reverses a 2023 FDA decision that removed those peptides from the approved list for compounding due to safety and efficacy concerns. The policy was posted to the Federal Register this week, with final publication set for October 30.
arstechnica.com
· 2026-10-28
FDA scientific staff largely opposed a policy that would have made it easier for Americans to obtain unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., according to six people familiar with its development. Agency officials reportedly warned that career scientists had serious safety concerns and would not endorse a regulation declaring the peptides safe, and staff said they had limited input in drafting the policy.
fastcompany.com
· 2026-10-28
Samsung has received regulatory clearance from the US FDA and Korea's MFDS for an advanced sleep apnea detection feature on its wearables. The feature uses an AI algorithm to count breathing disturbances per hour during sleep and categorizes results as mild, occasional, or frequent. It will roll out in November to the Galaxy Watch Ultra 2, Watch 9, and Galaxy Ring in South Korea, with older models like the Watch 8 and Watch 7 to follow via software updates.
androidauthority.com
· 2026-10-28
A Nature editorial, drawing on two accompanying news features, highlights emerging efforts to personalize mental-health treatment and develop psychedelic therapies as potential responses to a global mental-health crisis affecting over a billion people. The editorial notes the FDA has recently clarified evidence standards expected in psychedelic drug trials ahead of possible regulatory approval.
nature.com
· 2026-10-28
The FDA has issued a recall of more than 44,000 cans of Great Value fruit cocktail sold at Walmart, citing concerns about elevated lead levels. The affected cans were shipped to stores across seven US states.
fastcompany.com
· 2026-10-27
Eli Lilly announced in July plans to acquire psychedelic-medicine developer AtaiBeckley for up to $3.8 billion, targeting its lead drug BPL-003 for treatment-resistant depression. The deal follows AbbVie's $1.2 billion acquisition earlier in 2025 of Gilgamesh Pharmaceutical's short-acting psychedelic bretisilocin, signaling renewed big-pharma interest despite the FDA's 2023 rejection of an MDMA-based PTSD treatment.
nature.com
· 2026-10-27
Startup Radical Numerics has started an FDA-authorized clinical trial using bacteriophages designed by artificial intelligence to treat a patient's infection. CEO Dr. Eric Nguyen says the approach could create a virus tailored to a specific infection in days, but the research has not yet been peer-reviewed and success is not guaranteed.
science.slashdot.org
· 2026-10-22
Pharmacologist Thomas Burris and colleagues created a compound that activates a muscle receptor normally boosted by exercise, producing mice with greater endurance and possible cognitive and heart-failure benefits; Burris founded Pelagos to pursue a clinical trial. Separately, biotech firm Cambrian Bio reported in June that its drug ATX-304 raised metabolism and cut liver and belly fat in obese, prediabetic patients by activating an energy-sensing cellular switch.
technologyreview.com
· 2026-10-21
Quest Diagnostics will roll out an at-home HPV self-collection test using BD's Onclarity assay to patients across the U.S. starting next year. The FDA cleared the test for home use in April, allowing women to collect a sample themselves instead of undergoing an in-clinic pelvic exam.
fastcompany.com
· 2026-10-20
GoKawiil